Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1045"

Predicate	Value (sorted: none)
rdf:type	?:Evidence
rdf:type	?:Item
rdfs:label	"evidence_1384"
?:Evidence_type	?:EV_PK_DDI_NR
?:Evidence_assump_list_id	"186"
?:Evidence_enzyme_system	""
?:claim_assumed_valid_for_evidence_application_evidence_1384	?:dextromethorphan_in_viVo_probe_substrate_of_enzyme_cyp2d6
dc:creator	"boycer"
dc:date	"06/20/2009 14:58:06"
?:content	"route of administration: oral study duration: "dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release (150 mg twice daily) or matching placebo. Subjects quit smoking 3 days before the second dextromethorphan administration." population: 21 smoking, 9 female, 11 male tested for known CYP450 polymorphisms? yes ... all participants were considered CYP2D6 extensive metabolizers according to dextromethorphan:dextrorphan metabolite ratio ages: 21 - 40 NOTE: "24-hour period preceding each laboratory visit. Two subjects reported taking medications that could potentially affect CYP2D6 metabolism and therefore alter bupropion concentrations (one reported use of hormone replacement therapy and another oral contraceptives)." description: "Among those taking bupropion, DM/DX ratio in- creased significantly at the second assessment relative to the first (0.012 � 0.012 vs. 0.418 � 0.302; P < 0.0004) (Fig. 1). No such change was observed in those randomized to placebo (0.009 � 0.010 vs. 0.017 � 0.015; P = NS). Of those receiving bupropion, 46% (6/13) were phenotypically poor metabolizers after treatment.""
rdfs:seeAlso	?:15876900

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl

The resource appears as object in one triple:

{ bupropion_inhibits_cyp2d6, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1384 }

Context graph